A U.S. federal appeals court today invalidated the patent on Altace, a widely prescribed drug to treat high blood pressure. This clears the way for low-cost generic versions of the drug to hit the market immediately. King Pharmaceuticals, the company that makes Altace, is asking for a rehearing, but in the meantime it may lose its window of opportunity to “upgrade” Altace patients to a reformulated (and newly patented) version it was it planning on introducing in 2008. [Reuters]
By cwalters September 14, 2007
More From Consumerist
- FDA Closer To Approving Twice-Rejected Female Libido Drug
- FDA Approves First “Biosimilar” Drug. Could Drive Down Cost Of Most Expensive Medications
- FDA Finally Warns Drug Company Against Selling Antibiotic As A Pig-Fattener
- White House Acknowledges Health Risk Of Antibiotics Overuse; Critics Say It Fails To Fully Address Problem
- Why Does A Tube Of Cold Sore Cream Cost $2,500?